KAISER PERMANENTE.

Kaiser Permanente Medical Center, San Francisco Northern California Region

THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION. Its use is restricted to employees with a need to know and third parties with a need to know and who have signed a non-disclosure agreement.

1

Standard Operating Procedure

| Title: | TPMG SFO Laboratory Quality Control Policy – | Procedure Number SFOSOP- |
|--------|--|--------------------------|
| | Quantitative Assays | 0288 |
| | | Revision: 1 |

| Department: Chemistry Coagulation Hematology Immunohematology Microbiology Point-of-Care Testing Quality System Urinalysis Area: | Approved & Released Standard Operating Procedure | Implementation Date: 07/15/2019 |
|---|---|---------------------------------|
|---|---|---------------------------------|

Type of Document:

Review Period - 340 Days

RWLQCWI-2190 Rev1


Г


Laboratory Quality Control Policy – Quantitative Assays

| Sections | 1. Purpose |
|----------|---|
| | 2. Scope |
| | 3. Definition of Terms |
| | 4. QC Policy Statement |
| | 5. Laboratory Quality Programs |
| | a. Intra-laboratory QC Program |
| | b. Inter-laboratory QC Program |
| | c. Individualized Quality Control Plan (IQCP) |
| | 6. Quality Control: |
| | a. Handling and Preparation |
| | b. Level Selection |
| | c. Frequency |
| | 7. New QC Lot Validation |
| | a. Establishing New Lot Mean |
| | b. Establishing New Lot Range |
| | c. Levey-Jennings Chart On-board the Analyzer |
| | d. QC Limits in Cerner Millennium |

| | 8. QC Rules |
|----------|---|
| | a. Purpose of QC Rules |
| | b. Westgard Rules |
| | c. Westgard Rule Flowchart |
| | 9. QC Performance, Recording, Review & Monitoring |
| | a. QC Performance |
| | b. QC Recording |
| | c. QC Review: Daily, Weekly, Monthly |
| | d. Shift and Trend |
| | e. QC Monitoring |
| | f. Peer Group QC Comparison |
| | g. QC Range Adjustment |
| | 10. QC Failure Workup |
| | a. General Troubleshooting Approach |
| | b. QC Failure Workup (QC Ranges Established |
| | Based on Lab's Own Data) |
| | c. QC Failure Workup (Tests with Expanded QC |
| | Ranges) |
| | 11. Patient Impact Assessment |
| | a. Criteria for Lookback |
| | b. Patient Lookback (Analytical Error Due to |
| | Calibration, Reagent or Instrument Problem) |
| | c. Patient Lookback (Missed QC) |
| | 12. Appendix |
| | a. Clinically Acceptable Limits for Chemistry Tests |
| | b. Clinically Acceptable Limits for Coagulation Tests |
| | c. Hematology Duplicate Manual Cell Count |
| | Acceptance Criteria |
| | |
| | d. Hematology Duplicate Automated Cell Count |
| | Acceptance Criteria |
| | e. Recommended Approach to Manage QC Performance |
| | |
| | f. QC "Do's and Don'ts" |
| | 13. References |
| 1. | Quality Control (QC) in the clinical laboratory is a system |
| Purpose | designed to monitor that each test system employed by the |
| i uipose | laboratory is as accurate and reproducible as initially validated |
| | and patient results reported can be used with confidence by |
| | the provider for patient care management. QC procedures |
| | detect analytical errors, and when used and monitored |
| | |
| | properly, alert testing personnel (CLS/MLT) to potential |
| | analytical problems for which patient test results should not be |
| | reported. |
| | |
| | |
| | |
| | The region wide Laboratory Quality Control Policy promotes |
| | standardized practice across Kaiser Permanente NCAL region |
| | and ensures accuracy and precision throughout the analytic |
| | phase of testing. The purpose of this policy is to provide better |
| | understanding of QC data and to guide testing personnel in |
| | making clear and logical decisions about accepting or |
| | rejecting patient test results based on predetermined |
| | specifications. |
| | |

| 2. Scope | This policy is applicable only to quantitative tests in the following specialties: | | | |
|----------------------------|--|--|--|--|
| | Ø Chemistry and Blood Gas Ø Hematology Ø Coagulation | | | |
| | This policy is applicable to the following licensed personnel: | | | |
| | Ø CLS (Clinical Laboratory Scientists) Ø MLT (Medical Laboratory Technicians) when the test(s) is within scope | | | |
| 3. | Abnormal Control: | | | |
| Definitio n of Terms | Ø A control product that contains a physiologically high or low concentration of an analyte. | | | |
| | Accuracy: | | | |
| | Ø The closeness of agreement between a measured quantity value and the target value such as accuracy- based reference value or peer group consensus mean. The closeness of measurements to the true value is indicative of accuracy of the assay. | | | |
| | Bias: | | | |
| | Ø Systematic discrepancy between a measurement and the true value. Bias is a measurement of inaccuracy of a test system. A negative or positive bias is an estimate of a systematic measurement error. | | | |
| | | | | |
| | Coefficient of Variation (CV): | | | |
| | Ø A measure of the ratio of standard deviation (SD) to the mean. CV is concentration independent and is useful to assess the precision of a test. CV is calculated by dividing the SD by the mean and multiplied by 100. CV is the SD expressed as a percentage of the mean. Ø Formula: | | | |
| | CV = (s ÷ x) 100 Where: s = standard deviation x = mean | | | |





occurrence, whereas corrective action is taken to prevent *recurrence*.

Quality Assessment:

Ø An overall management plan to assess the integrity of the entire process. Quality assurance is intended to ensure that the right test is carried out on the right specimen, and that the right result and right interpretation is delivered to the right person at the right time.

Quality Control:

Ø The set of mechanisms, processes, and procedures designed to monitor the measuring system to ensure the results are reliable for the intended clinical use.
 Quality Control is used to monitor both the accuracy and precision of the assay to provide reliable results.

Quality Control Log:

Ø A written or computerized listing of successive quality control results.

Quality Control Peer Group:

Ø A group of labs that uses the same instruments, analytical method, reagent and use the same lot of control material.

Quality Control Material:

- Ø A stable material, liquid or freeze-dried of human, animal or chemical origin that are used to monitor the quality and consistency of the analytical process. A QC sample is designed to simulate a patient sample and is intended for use to monitor the reliability of test system and to alert CLS/MLT when the test system performance is outside the pre-determined specifications. Prepared controls come in either assayed or unassayed forms.
 - o Assayed Control Material:

Assayed control materials generally come with an assay sheet of expected values for analytes assayed by various methods and instrument systems. These assay sheets usually list, for each constituent present, expected mean values and expected ranges. These ranges are provided only as guideline when the laboratory establishes its QC ranges. <u>The manufacturer's</u> <u>ranges should not be used as the laboratory's</u> <u>ranges.</u> The laboratory must establish a valid acceptable range by repetitive analysis that includes previously tested control material.

o Unassayed Control Material:

Control material that has no assigned analyte values provided by the manufacturer. The laboratory must establish a valid acceptable range by repetitive analysis that includes previously tested control material.

Quality Control Range:

Ø It is the upper and lower QC limits. QC range is a measure of dispersion which is the difference between the largest and smallest acceptable limits of quantitative characteristic in a given sample. QC range usually represents a ±2SD or ±3SD range unless the range is intentionally expanded.

o Expanded QC Ranges:

These are evidence-based QC ranges, inflated QC ranges, manufacturer's ranges where QC ranges are not established based on lab's own data. The QC ranges have limits that are greater than +/- 3 times the true SD.

Random Error:


Ø Any sporadic, non-reproducible and significant deviation from the lab mean that cannot be explained.


Reagent:

 Any substance in a test system other than a solvent or support material that is required for the target analyte to be detected and its value measured in a sample. Examples of reagent are: calibrators, quality controls, etc.)

Standard Deviation (SD):

- Ø The average difference from the mean over time. A statistic which quantifies the dispersion of values around the mean within a specified set of values.
- Ø Formula:





| | 4.4 4.4 4.4 4.2 4.1 4 |
|------------------------------------|---|
| | Westgard Rules: Ø A set of statistical rules used separately or in concert with each other to evaluate QC performance. |
| 4. Quality | Z-Score: Ø A statistic that compares each data point to the laboratory mean and SD Ø Formula: Z = (QC result – Lab mean) / Lab SD TPMG SFO Laboratory is committed to complying with California state, federal regulations and CAP quality control |
| Control Policy Stateme nt | requirements. Ø The laboratory Quality Control procedures detect immediate errors that occur due to test system failure, adverse environmental conditions, and operator performance. Ø The laboratory Quality Control procedures monitor over time the accuracy and precision of test performance that may be influenced by changes in test system performance and environmental conditions, and variance in operator performance. |
| 5.Laborato ry QC Programs | A. Intra-Laboratory QC Program: Ø The Intra-Laboratory Quality Control Program uses commercially available control materials or, if applicable (e.g. Coagulation), pooled, pre-analyzed patient specimens to assess the reliability of day-to- day accuracy and precision of testing system. |
| | B. Inter-Laboratory QC Program: Ø This is provided by QC or instrument manufacturers to compare the laboratory's quality control data with other laboratories using the same quality control material on the identical instrumentation for statistical analysis and comparison to other laboratories. It is highly recommended to enroll in an Inter-Laboratory Quality Control Program. |
| | C. Individualized Quality Control Plan (IQCP): Ø IQCP is a risk-based approach that allows flexibility in QC frequency for qualified tests. IQCP must include a risk assessment (RA), Quality Control Plan (QCP) and Quality Assessment (QA) as required by CMS and CAP. It provides structure and guidance to perform this evaluation and determine the best QC protocol for a laboratory. |

| | Ø Only tests that qualify under CAP IQCP are permitted to reduce QC frequency below CLIA minimum requirement via IQCP evaluation process. CAP IQCP Qualifications: Non-waived and non-pathology tests Test that has an internal or electronic control Organism QC for Microbiology media Ø IQCP has been implemented region wide for non- waived point of care tests such as i-Stat and microbiology media QC. Contact the ALAD-LQC and/or Regionwide NCAL-LQC if assistance is needed to determine IQCP qualification or for IQCP development. |
|-----------------------|---|
| 6. Quality Control | A. QC Handling and Preparation: Follow the manufacturer's instructions in handling and preparation. Frozen controls must be completely thawed prior to use. Mix controls by gentle inversion prior to dispensing. If lyophilized, put the date when the control was reconstituted. Some controls may require shorter expiration date than what is originally stated on the label upon opening, thawing or reconstitution. Follow the manufacturer's instructions in determining in-use expiration date. Keep controls tightly capped when not in use. If controls require refrigeration, put the control vials back in the refrigerator as soon as possible after use. Discard expired controls appropriately. NCAL LQC recommends putting the open date, expiration date and CLS/MLT initials on the control vial or tracking log. G Refer to each test procedure. A minimum of two levels of control is used in all quantitative assays. Some assays (e.g. beta hCG) have additional control on monitor the accuracy of on-board dilution. Control material should have constituent concentrations at normal and abnormal levels and should be within the reportable range of each assay. C QC Frequency: Follow the regulatory and manufacturer recommendations, whichever is more stringent. For most tests, CLIA and CAP require that QC be tested, at minimum, every 24 hours that testing occurs. QC must also be tested after calibration, after a change in reagents, after test system maintenance and after replacement of a critical part (e.g. lamp, probe, photometer, incubator replacement). |


| | | Ø | Chemistry QC Frequency: |
|-----------|----|----|--|
| | | ~ | v Routine Chemistry – for most tests, every 24 |
| | | | hours; electrolytes and creatinine, every 8 hours |
| | | | v Osmolality – every 24 hours |
| | | | v Blood Gas – every 8 hours |
| | | | |
| | | Ø | Hematology QC Frequency: |
| | | ~ | v Two to three levels of liquid QC every 8 hours |
| | | | |
| | | _ | |
| | | Ø | Coagulation QC Frequency: |
| | | | v Two levels of liquid QC every 8 hours |
| | Α. | | tablishing New Lot Mean: |
| 7. New QC | | Ø | Approximately 30 days before the current lot of |
| Lot | | | controls expires, establish a target mean by replicate |
| Validatio | | a | testing. |
| n | | Ø | For assayed and unassayed controls of chemistry and |
| | | | coagulation tests, concurrent testing of new lot and |
| | | | current lot of QC materials is required. Collect QC |
| | | | data over an extended period, such as 30 days, so that |
| | | | data reflects variations normally occurring in routine |
| | | a | operation. |
| | | Ø | Evaluation should include: |
| | | | v Several bottles of control material |
| | | | v Different calibrations, whenever possible |
| | | | v Several operators |
| | | | v Change of environmental conditions, such as |
| | | Ø | temperature fluctuations For assayed controls, target mean must fall within the |
| | | Ø | manufacturer's range. Assigned values provided by the |
| | | | manufacturer should be used only as guides and not |
| | | | as a replacement for the target values established by |
| | | | the laboratory. |
| | | Ø | Invalid results (obvious outliers, results >3SD, |
| | | ~ | evaluation results from runs where current lot of QC |
| | | | fails, wrong QC vial, and/or deteriorated QC material) |
| | | | should be omitted from the calculations of the mean. |
| | | | |
| | B. | Es | tablishing New Lot Range: |
| | | | Use the laboratory's QC data to calculate the mean, |
| | | | SD and CV. |
| | | Ø | For most tests, a \pm 2SD range is acceptable but for |
| | | | Hematology, a \pm 3SD range is more appropriate (i.e. |
| | | | instruments for CBC, if lab is using own QC data). |
| | | Ø | QC range that is intentionally expanded beyond ±3SD |
| | | | by the laboratory must be justified and approved by the |
| | | | LMD or manager overseeing the department. |
| | | | Westgard Rules do not apply to inflated QC ranges. |
| | | Ø | QC range that is intentionally inflated by the |
| | | | manufacturer (e.g., Evidence-Based QC of Sysmex |
| | | | analyzers) can be used without additional approval. |
| | | | Follow Sysmex instructions to establish QC ranges. |
| | | | Westgard Rules do not apply to EBQC ranges. |
| | | Ø | In emergency situations, the new lot QC range of a |
| | | | stable method can be estimated. Repeat the new lot |
| | | | control at least 10 times over 5 days to obtain the new |

| | mean and use the cumulative CV% to estimate the new SD. |
|------------|---|
| | Formula: |
| | v New Lot SD = New Lot Mean x cumulative CV% |
| | Ø QC ranges between two identical instruments must be, |
| | if not identical, close with each other (i.e. QC Means |
| | between 2 identical instruments using the same |
| | calibrator/reagent and run by same group of testing personnel are within 0.5 to 1.0 SD). |
| | |
| | C. Levey-Jennings Chart On-Board the Analyzer: |
| | Ø The mean and SD of the analyzer QC program, when |
| | available, must be updated to reflect the current QC |
| | range to allow CLS/MLT to use the Levey-Jennings chart to appropriately evaluate QC performance. |
| | chan to appropriately evaluate QC performance. |
| | D. Cerner Millennium (CM) QC Program, when applicable: |
| | Ø The mean and SD in CM must be updated to reflect |
| | the current QC range to allow CLS/MLT to use the Z- |
| | Scores to appropriately evaluate QC performance. |
| | |
| | |
| | |
| | A. Purpose of Quality Control Rules: |
| 8.QC Rules | Ø Use QC rules in decision-making based on one or |
| | more QC measurements to determine whether the |
| | method is performing in a stable (in control) or unstable (out of control) state. |
| | Ø Use QC rules to detect a change from stable analytic |
| | method (systematic error), such as shift or trend. |
| | Ø For test system where manufacturer requires all three |
| | levels of quality control values are within acceptable |
| | ranges, run is rejected when this criterion is not met. Ø For test system where the additional third quality |
| | control material is for monitoring dilution accuracy, |
| | undiluted patient results are acceptable when both |
| | undiluted quality controls are in range. Diluted patient |
| | results are acceptable when all three quality controls (undiluted and diluted controls) are in range. |
| | |
| | B. Westgard Rules: |
| | Ø There is no regulatory or accreditation requirement to use all (or any) Westgard Rules, but the laboratory |
| | must have rules to indicate when method is out of |
| | control and needs attention, including corrective action |
| | and patient impact assessment. |
| | Ø Westgard Rules can be used only when QC range is |
| | established using the laboratory's own data without intentional expansion. |
| | Ø Westgard rules do not apply if the lab is using peer |
| | group range, evidence-based range, inflated range and |
| | manufacturer's range. These ranges are usually wider |
| | than the laboratory's range. |

NCAL TPMG SFOO Labs Standardized QC Rules:

1_{2s} Rule

- Ø First data point of 20 is outside the ± 2 SD limits.
- Ø The second control is in range.
- Ø This rule warns that random or systematic error may be present in the test system, therefore, the relationship between this value and other QC results within the current analytical runs must be examined. If no relationship can be found and no source of error can be identified, a single a control value outside the ±2s limits is an acceptable random error.



Ø Actions:


- ü Review Levey-Jennings Chart for shift and/or trend.
- ü If none, repeat QC one time only to confirm random error.
- ü If random error is confirmed, report patient results; otherwise, hold patient results and start troubleshooting (Section 10).

Ø Monitor:

- ü Inspect preceding QC data if other rules are violated (i.e. 1_{3s}, 2_{2s}). If so, reject the run.
- ü Follow Westgard Rule Flowchart (Section 8-C).

1_{3s} Rule

- Ø Data point that is outside ± 3 SD violates this rule.
- Ø Could be random error or beginning of a systematic error.






- ü Review Levey-Jennings Chart for shift and/or trend.
- ü Investigate and do not report patient results.
- ü Assess the need for patient lookback after QC issue is resolved.


2_{2s} Rule

Ø <u>2-2s Within Same Run</u>: 2 of 2s violations from two levels of controls within the same run.



Ø Actions:

- ü Review Levey-Jennings Chart.
- ü Investigate and do not report patient results.
- ü Assess the need for patient lookback after QC issue is resolved.
- Ø <u>2-2s Across Run</u>: 2 of 2s violations from successive runs of the same control




Ø Actions:


- ü Reject the run, do not report patient results.
- ü Investigate, identify cause of out-of-control.
- ü Perform patient lookback (Section 10, Patient Impact Assessment).

R-4_s Rule

Ø There is at least a difference of 4s between the control values within a single run.



- ü Patient results can be reported.
- ü Check peer group mean, if available.
- ü Troubleshoot/ recalibrate the instrument.



last acceptable QC may need to be assessed (Section 8, QC Rules).

- Ø Weekly and Monthly
 - The Lab Medical Director or delegated section supervisor (TS, TC, GS) is responsible for reviewing and assessing QC results at intervals adequate to assess the performance of analytical process. QC review for each test is documented and may occur electronically or on paper that is readily accessible.
 - <u>Weekly QC review</u> is performed to check for outliers, appropriate use of Westgard Rules, corrective actions, QC omission, shifts and trends.
 - <u>Monthly QC review</u> is performed to monitor test accuracy and precision over time. The activities include monitoring changes in CV, mean or SD and maintenance of QC ranges (refer to E, F & G of Section 9).
 - The review of quality control data for tests that have an IQCP approved by the Lab Medical Director must include an assessment of whether further evaluation of the risk assessment and quality control plan is needed based on problems identified (e.g. trending for repeat QC failures, etc.).

D. Shift, Trend and Bias:

- Ø Shift
 - It is a shift when QC values move suddenly upward or downward from the mean and remain for at least 7 consecutive points.
 - v Action:
 - ü Check if new reagent or QC materials are used.
 - ü Check reagent and control lot number.
 - ü Check reagent and control expiration date.
 - ü Check for instrument issues such as missed instrument maintenance, change in internal temperatures, or dirty cuvettes.
 - ü Check the calibrator used at the time of calibration.
 - ü Observe for any shift in QC value due to calibration.
 - ü Recalibrate the analyte and see if the shift is corrected by calibration.
 - When QC shifted upon reagent lot change, perform patient comparison (n=20 with high and low values) to confirm that QC shift is limited to control material and that patient results are not impacted.
 - o Note:

For tests that can tolerate result shift when reagent lot change (such as BNP), it is acceptable to adjust QC ranges. For tests that cannot tolerate result shift upon lot change (such as

| | | ponin), the reagent ected. | will need to | De |
|------------------------------|---|--|--|---------------------------|
| | rend v It is a trend wh down from the same direction v Action: ü Check for ü Check for ü Check for u check pac handling in ü Open a ne ü If necessa | nen QC values gradu mean and continue for at least 7 conse failing calibration. reagent (calibrator, t wash buffer) expirat on. kage insert for contr | moving the ecutive point esting reage ion date or rol stability a naterial. | ent, and |
| E. QCI | Monitoring: | | | |
| F. Peer Ø L a | monthly to def imprecision. Monthly Mean term performa Group QC Comp Jse QC provider o ggregated QC da issessment across Use peer grou accuracy/bias QC ranges, m Sysmex Evide Use the peer g house method | r instrument manufa ta to perform results s peer laboratories. p data (SDI & CVR) and precision for tes anufacturer's QC ran nce-based QC rang group data to verify t against peers. | and analyt racked for lo m. comparabil to assess sts with infla nges, and es. | ic ong lity ated |
| Peer Gro | up Comparison (| <u> Guideline:</u> | | |
| SDI | Acceptable | Acceptable to Marginal | Marginal | Unacceptable |
| 1.25 or less (target = 0) | V | | | |
| 1.26 - 1.49 | | √ #1 | | |
| 1.50 - 1.99 | | | √ ^{#2} | |
| 2.0 and above | 2 | | | V ^{#3} |
| L | | | | |

| CVR | Better than Peer Group | Imprecision Alert | Imprecision | Unacceptable |
|-------------|---------------------------|----------------------|-----------------|-----------------|
| < 1.0 | V | | | |
| > 1.0 - 1.5 | | V ^{#1} | | |
| >1.5 - 2.0 | | | √ ^{#2} | |
| > 2.0 | | | | V ^{#3} |

Actions:

#1: Some investigation of the test system may be required#2: Investigation of the test system is recommended#3: Investigation and remedial action are required

Note:

10.**QC**

Failure

Workup

Comparison with the peer does not remove the requirement for daily, weekly and monthly in-house QC review.

G. QC Range Adjustment


- Ø Testing personnel are NOT authorized to adjust the QC mean or SD.
- Ø QC range does not need to be adjusted monthly.

| Ø | QC range does not need to be adjusted monthly. |
|-------|---|
| Ø | QC range established under Section 7 (New QC Lot |
| | Validation) needs to be verified over time of stable |
| | performance (e.g. two to three months). This is to |
| | confirm the range is not too narrow or too wide. |
| | Cumulative data and peer group data can be used as a guide to fine tune the QC range. |
| Ø | When indicated, investigate the possible cause(s) of |
| | the QC change prior to any adjustment. Any change in |
| | accuracy, such as shift or trend, will reflect a change in |
| | the mean value of the control. Adjusting the mean |
| | without investigating the cause of the QC change will |
| | only mask the problem and error in analytical process |
| | may not be detected. |
| Ø | QC mean may be adjusted only after confirming that |
| 2 | shift is due to matrix of the control material. (Refer to |
| | "Shift" under D of Section 9) |
| ø | , |
| 2 | data points fall between 1 and 2 SD and -1 and -2 SD |
| | for a period of time. |
| ø | · · · · · · · · · · · · · · · · · · |
| 2 | manager or designee overseeing the department. |
| | manager of designed everedening the department. |
| | |
| A. Ge | neral Troubleshooting Approach: |
| Ø | QC Material |
| | ü Correct material, lot number, level? |

ü Correctly prepared?ü Levels not interchanged?

ü Not expired?

| 1 | |
|---|--|
| | ü Analyzed within known stability period after preparation? |
| | ü Correctly stored? |
| Ø | Reagents ü Correct material, lot number? ü Correctly prepared? ü Correctly loaded and used? ü Not expired? ü Correctly stored? |
| Ø | Calibrator ü Correct material, lot number? ü Correctly prepared, used and stored after use? ü Correct number and order? ü Correct calculations and settings? ü Not expired? |
| Ø | Analyzer ü Correct and timely maintenance? ü Any recent changes? ü Materials within stated on-board stability? ü Visual inspection for problems? |
| Ø | Environment ü Proper water system, acceptable water quality? ü Temperature and humidity at proper levels |
| | C Failure Workup: Applicable to QC ranges that are established based on lab's own data. |
| | When QC Flags occur on ranges set up appropriately |
| | Review L-J chart and/or Z-Score Treat first time outliers as Westgard 12, violation |
| | Review Lab Records |
| | Operator Error? Ctrl / Cal Problem? New Rgt Pack or Lot? Done or Overdue? |



| | Lookback is performed <u>after</u> the problem is corrected or issue is resolved. V Depending on the root cause of the QC outlier, spot check or repeat all patients since the last acceptable run. V When QC failure was corrected, repeat all patients since the last acceptable run. V Consult with Clinically Acceptable Limits and Lab Medical Director to determine if patient lookback results are acceptable and error correction (ECR) is indicated. V Retesting of patient samples may be performed on the second analyzer with confirmed accuracy. C. Patient Lookback (Missed QC on Previously Reported Patient Results) Ø Retest preserved or stable patient samples, if available. Ø If patient samples are no longer available, re-evaluate results by: V Comparison of patient population means between the run in-question to historical patients. Selected patients should have the low-high end of AMR and/or medical decision points. V Correlation with either clinical findings or prior results to see if there are consistent biases (i.e. all results higher or lower currently than previously) for the test in question. V Consult with Clinically Acceptable Limits and Lab Medical Director to determine if patient lookback results are acceptable and error correction (ECR) is indicated. |
|---------------------|---|
| 12. Ap pendix | Clinically Acceptable Limits Ø The clinically acceptable limits are acceptance criteria for patient comparison/lookback studies to determine the need to perform error correction when troubleshooting the analyzer. Ø Clinical acceptable limits are not used to evaluate reagent lot acceptability. Ø The routine Chemistry limits are based on the recommendations of Regional Laboratory Chemistry Technical Team (Dr. Dlott, 6/8/05). |
| | Appendix A: <u>Clinically Acceptable Limits for Chemistry</u> <u>Tests</u> |
| | Routine Chemistry: |
| | |

| | TEST | Clinically Acceptable Limit |
|----|----------------|---------------------------------|
| 1 | Albumin | ± 10% |
| 2 | Alk-P | ± 10% |
| 3 | ALT | ± 10% |
| 4 | Amylase | ± 10% |
| 5 | AST | ± 10% |
| 6 | Bili-T | ± 0.2 mg/dl or 10% |
| 7 | BUN | ± 2 mg/dl or 10% |
| 8 | Calcium, total | ± 0.3 mg/d10r 5% |
| 9 | СК | ± 10% |
| 10 | CL | ±5% |
| 11 | Cholesterol | ± 10% |
| 12 | CO2 | ± 10% |
| 13 | Creatinine | ± 0.1 mg/dl or 10% |
| 4 | Fructosamine | ± 10% |
| 15 | GGT | ± 10% |
| 16 | Glucose | ±5 mg/dl or 5% |
| 17 | HDL -C | ± 10% |
| 18 | Iron | ± 10% |
| 19 | к | ± 0.3 mmol/L or 5% |
| 20 | Lactate | ± 0.2 mmol/L or 10% |
| 21 | LDH | ± 10% |
| 22 | LDL-C | ± 10% |
| 23 | Lipase | ±20% |
| 24 | Mg | ± 10% |
| 25 | NA | ±2 mmol/L (serum) or 5% (urine) |
| 26 | Phosphorus | ± 0.3 mg/dl or 5× |
| 27 | Total Protein | ± 10% |
| 28 | Triglycerides | ± 10% |
| 29 | UIBC(TIBC) | ± 10% |
| 30 | Uric acid | ± 10% |
| 31 | CK-MB | ±5% |
| 32 | Troponin I | ± 5% |

TDMs:

| | TEST | Clinically Acceptable Limit |
|----|----------------|-----------------------------|
| 33 | Carbamazephine | ± 10% |
| 34 | Digoxin | 0.1 mmol/L or 10% |
| 35 | Gentamicin | ± 10% |
| 36 | Lithium | 0.1 mmol/L or 10% |
| 37 | Phenobarbital | ± 10% |
| 38 | Phenytoin | ± 10× |
| 39 | Theophylline | ± 10% |
| 40 | Tobramycin | ± 10% |
| 41 | Valproic Acid | ± 10% |

Appendix B: <u>Clinically Acceptable Limits for Coagulation</u> <u>Tests</u>

| TEST | Clinically Acceptable Limit |
|------------|-----------------------------|
| PT | ± 5% |
| APTT | ± 5% |
| Fibrinogen | ±7% |

Appendix C: <u>Hematology Duplicate Manual Cell Count</u> <u>Acceptance Criteria</u>

| # of Cells Counted (Manual) | Duplicated Counts Agree By | Or Within +/- (whiche∨er is larger) |
|--------------------------------|-------------------------------|--|
| <5 | 50% | 2 |
| 6 to 10 | 30% | 3 |
| 11 to 20 | 25% | 5 |
| 21 to 30 | 20% | 6 |
| >30 | 15% | |

Appendix D: <u>Hematology Duplicate Automated Cell Count</u> <u>Acceptance Criteria</u>

| Automated Count | Duplicated Counts Agree By | Or Within +/- (whichever is larger) |
|-------------------|-------------------------------|--|
| WBC | ± 0.5 | 5% |
| RBC | ± 0.2 | 2% |
| HGB | ± 0.4 | 2% |
| HCT | | 2% |
| PLT (0 - 30K) | ± 5K | |
| PLT (30K - 70K) | ± 10K | |
| PLT (71K - 150K) | ± 20K | |
| PLT (151K - 600K) | ± 25K | |
| PLT (>601K) | ± 50K | |
| PMN | 6 | |
| LYMPH | 6 | |
| MONO | 6 | |
| EOS | 3 | |
| BASO | 3 | |

Appendix E: <u>Recommended Approach to Manage QC</u> <u>Performance</u>

- ü QC ranges that are appropriately established.
- ü QC is monitored for its long-term performance.
- ü Comprehensive knowledge of the test system/analyzer, reagents, and control materials.
- ü Some tests are more sensitive to changes in reagent lot, control lot, and environmental conditions.
- ü Testing personnel performs troubleshooting in a timely manner and corrective action is documented according to the laboratory policy.
- ü Supervisors ensure technical issues are resolved and normalcy is returned.

Appendix F: QC Do's and Don'ts

| DO's | | DON'Ts |
|----------------------------|--|---|
| ü | Do review L-J Chart or z- score whenever QC is out. | X Do not blindly repeat QC multiple times until the control passes. |
| ü | Do Perform initial assessment. | X Do not repeat QC without initial assessment. |
| ü | Do repeat control after investigation and corrective actions are taken to confirm resolution. | X Do not change range to fit the QC data without patient assessment. |
| ü | Do document what you did to correct the problem. | |
| 2. 3. 4. 5. 6. | CLIA Regulations CFR 493. Statistical Quality Control fo Procedures, Approved Guid Definitions – 4 th Edition, C24 Laboratory Standards Institu CAP All Common Checklist; Checklist, August 21, 2017 2018 Focus on Compliance, Right, D. Robert Dufour, Gre 2018 Basic Lessons in laboratory Cooper, BioRad Laboratorie 2008 Basic QC Practices 4 th Edition Inc., 2016 Basic Quality Control: QC 10 Medical Group, Northern Ca and Compliance, Shiu-Land | r Quantitative Measurement eline: Principles and 4, Wayne, PA, Clinical and utes, 2016 c Chemistry and Toxicology , Quality Control: Getting It egory Gagnon, March 21, Quality Control, Greg es, Quality Systems Division, on, James O. Westgard QC 01, The Permanente alifornia Laboratory Quality |

Associated Documents:

External Documents

Associated Quality System Documents - None

Document Revision History:

| Revision: 1 | Date Created: 04/12/2019 Date of Last Revision: | Last Approval Date: 07/15/2019 |
|-------------|--|--------------------------------|
| | 07/15/2019 | |

| Document Author: | |
|------------------------|--|
| Maureen R | |
| Fitzgibbons/CA/KAIPERM | |

Reason for Change:

| Revision: | Sec/Para Changed | Change Made: | Date |
|-----------|------------------|--|----------------|
| 1 | N/A | Initial Issue of Document | 04/12/2 019 |
| 2. | 11.A and B | A.CriteriaforPatientLookbackMissedQCQC failure requiring instrument service or maintenanceØ22s rule violation, in cases where the cause cannot be resolved with new QC/CAL material. For 2-2s where the cause is identified, the investigation will be reviewed and it will be in the judgment of the Supervisor, ALAD, or Medical Director to | ļ |
| | 8.C | Depending on the root cause of the QC outlier, spot check or repeat all patients since the last acceptable run. When QC failure was corrected, repeat all patients since the last acceptable run. W Consult with Clinically Acceptable Limits and Lab Medical Director to determine if patient lookback results are acceptable and error correction (ECR) is indicated. Retesting of patient samples may be performed on the second analyzer with confirmed accuracy. Westgard Rule Flowchart is replaced with new chart. | |
| | | | |
| | | | |

Approvals:

Name: Elizabeth M Hosfield/CA/KAIPERM Title: Chief of Pathology; CLIA Director Jul 15, 2019 12:22:09 PM PDT - Approved by: Elizabeth M Hosfield/CA/KAIPERM